date/time interval
- October 1, 2022 - September 30, 2027
A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Grant
- Overview
- Affiliation
- View All
Overview
awarded by
total award amount
- CAD 218408